Infrapatellar fat pad-derived mesenchymal stromal cell product for treatment of knee osteoarthritis: a first-in-human study with evaluation of the potency marker

• Published in: Cytotherapy (Oxford, England) England), 2022-01, Vol.24 (1), p.72-85
• Main Authors: Chen, Hung-Hsuan, Chen, Yu-Chun, Yu, San-Ni, Lai, Wan-Ling, Shen, Yi-Shan, Shen, Pei-Chun, Lin, Siao-Han, Chang, Chih-Hung, Lee, Shing-Mou
• Format: Article
• Language: English
• Subjects: Adipose Tissue; anti-inflammation; first-in-human study; Humans; indoleamine-2,3-dioxygenase; infrapatellar fat pad-derived mesenchymal stromal cells; Injections, Intra-Articular; Knee Joint; Mesenchymal Stem Cells; osteoarthritis; Osteoarthritis, Knee - diagnostic imaging; Osteoarthritis, Knee - therapy; potency of MSCs
• ISSN: 1465-3249; 1477-2566
• DOI: 10.1016/j.jcyt.2021.08.006

Infrapatellar fat pad-derived mesenchymal stromal cells (IFP-MSCs) have not yet been used in a human clinical trial. In this open-label phase 1 study, patients with knee osteoarthritis (OA) received a single intra-articular injection of autologous IFP-MSCs. Safety was assessed through physical examination of the knee joint, vital signs, laboratory tests and adverse events. Efficacy was evaluated with regard to pain and function using questionnaires, x-ray and magnetic resonance imaging (MRI). Indoleamine-2,3-dioxygenase (IDO) expression in IFP-MSCs primed with interferon gamma was used as an in vitro potency measurement in investigating the correlations of clinical outcomes. Twelve patients with symptomatic knee OA were recruited. IFP adipose tissue was harvested from each patient's knee through surgical excision for IFP-MSC manufacturing. Cryopreserved IFP-MSCs (5 × 107 cells) were injected into the knee joint immediately after thawing. No significant adverse events were observed. Patients who received IFP-MSCs exhibited clinically significant pain and functional improvement at 48-week follow-up. The MRI Osteoarthritis Knee Score average was also significantly reduced from 100.2 before injection to 85.0 at 48 weeks after injection. The IDO expression of the primed IFP-MSCs of the 12 patients was correlated with clinical outcomes after injection. A single intra-articular injection of IFP-MSCs appears to be a safe therapy for treating knee OA and may improve disease symptoms. IDO measurement of primed IFP-MSCs has potential as a potency marker of MSC products for immunomodulatory therapy.